Overview

• Biontech reported a €415.8 million net loss for Q1 2025, with revenues of €182.8 million, reflecting declining COVID-19 vaccine demand.
• The company has revised its 2025 revenue forecast to €1.7–2.2 billion, down from earlier projections.
• Ramón Zapata has been appointed as the new Chief Financial Officer to help guide Biontech's financial strategy during its transition.
• Biontech is intensifying R&D efforts to file its first mRNA-based cancer therapy with the FDA by late 2025, aiming for approval in 2026.
• This strategic pivot marks a shift from pandemic-driven profits to a focus on oncology innovation, with significant restructuring underway.